Genetic basis of dyslipidemia in disease precipitation of coronary artery disease (CAD) associated type 2 diabetes mellitus (T2DM)

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 7, 2015, Pages 663-671

  Raj, Resal ^a   Bhatti, Jasvinder Singh ^b   Badada, Sanjay Kumar ^c   Ramteke, Pramod W ^a  

^a SAM HIGGINBOTTOM UNIVERSITY OF AGRICULTURE   (India)

^b SGGS College Sector 26   (India)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cardiovascular disease; Dyslipidaemia; Precipitation; Reactive oxygen species

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; APOLIPOPROTEIN B; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOCANNABINOID; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL; APOA5 PROTEIN, HUMAN; APOC4 PROTEIN, HUMAN; APOLIPOPROTEIN A; APOLIPOPROTEIN C; APOLIPOPROTEIN C3; ARYLDIALKYLPHOSPHATASE; CANNABINOID 1 RECEPTOR; CETP PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PON1 PROTEIN, HUMAN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL ORGANELLE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; GENE; GENETIC ASSOCIATION; GOLGI COMPLEX; HEPATITIS C; HUMAN; INSULIN RESISTANCE; INSULINEMIA; MITOCHONDRION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRECIPITATION; PRIORITY JOURNAL; REVIEW; RIBOSOME; TRIACYLGLYCEROL BLOOD LEVEL; COMPLICATION; G1 PHASE CELL CYCLE CHECKPOINT; GENETIC POLYMORPHISM; GENETICS; METABOLISM; RISK FACTOR;

ADIPONECTIN; APOLIPOPROTEIN C-III; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS A; APOLIPOPROTEINS C; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; G1 PHASE CELL CYCLE CHECKPOINTS; HEPATITIS C; HUMANS; MITOCHONDRIA; POLYMORPHISM, GENETIC; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, LDL; RISK FACTORS;

EID: 84943666231     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2630     Document Type: Review

References (139)

1. Joshi SR. Metabolic syndrome-emerging clusters of the Indian phenotype. J Assoc Physicians India 2003; 51: 445-446.
2. Mohan V et al. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res 2007; 125(3): 217-230.
3. Mohan V et al. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. J Assoc Physic India 2005; 53: 759-763.
4. Eliasson L et al. Novel aspects of the molecular mechanisms controlling insulin secretion. J Physiol 2008; 586(14): 3313-3324.
5. Thim L et al. Secretion and processing of insulin precursors in yeast. Proc Natl Acad Sci U S A 1986; 83(18): 6766-6770.
6. Woerle HJ et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin a1c values. Arch Intern Med 2004; 164(15): 1627-1632.
7. Monnier L, Colette C. Contributions of fasting and postprandial glucose to hemoglobin A1c. Endocr Pract 2006; 12(Suppl 1): 42-46.
8. Hamaty M. Insulin treatment for type 2 diabetes: when to start, which to use. Cleve Clin J Med 2011; 78(5): 332-342.
9. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes-causes, effects and coping strategies. Diabetes Obes Metab 2007; 9(6): 799-812.
10. Cryer PE, Irene E, Karl MM. Insulin therapy and hypoglycemia in type 2 diabetes mellitus. Insulin 2007; 2(3): 127-133.
11. A N A. Comparative performance of HbA1c 6.5% for FPG >7.0 vs 2 hr PG>11.1 criteria for diagnosis of Type 2 diabetes. Afr Health Sci 2011; 11(3): 421-426.
12. Gast KB et al. Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical: Atherosclerosis the NEO study. Atherosclerosis 2013; 229(2): 423-429.
13. Knights AJ et al. Adipokines and insulin action: a sensitive issue. Adipocyte 2014; 3(2): 88-96.
14. Yoon MJ et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes 2006; 55(9): 2562-2570.
15. Yamauchi T et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8(11): 1288-1295.
16. Ohashi K et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab 2014; 25(7): 348-355.
17. Katsuyuki Nakajima TN, Tokita Y, Nagamine T, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta 2011; 412(15-16): 1306-1318.
18. Rahim A et al. Proteomic analysis of the very low density lipoprotein (VLDL) transport vesicles. J Proteomics 2012; 75(7): 2225-2235.
19. Ware WR. The mainstream hypothesis that LDL cholesterol drives atherosclerosis may have been falsified by non-invasive imaging of coronary artery plaque burden and progression. Med Hypotheses 2009; 73(4): 596-600.
20. Zago V et al. Role of HDL in neutralizing the VLDL effect on endothelial dysfunction. Microvasc Res 2013; 89: 153-158.
21. Lee IT et al. High triglyceride-to-HDL cholesterol ratio associated with albuminuria in type 2 diabetic subjects. J Diabetes Complications 2013; 27(3): 243-247.
22. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28(Suppl 1): S4-S36.
23. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014; 37(Suppl 1): S14-80.
24. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
25. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36(Suppl 1): S11-66.
26. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006; 116(7): 1802-1812.
27. Butler AE et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52(1): 102-110.
28. Kim JA et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-1904.
29. Fariss MW et al. Role of mitochondria in toxic oxidative stress. Mol Interv 2005; 5(2): 94-111.
30. AlexMa Z, Zhao Z, Turk2 J. Mitochondrial dysfunction and β-cell failure in type 2 diabetes mellitus. Exp Diabetes Res 2012; 2012: 1-11.
31. Hamed S, Brenner B, Roguin A. Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2. Cardiovasc Res 2011; 91(1): 9-15.
32. Yin Z et al. The possible role of ribosomal protein S6 kinase 4 in the senescence of endothelial progenitor cells in diabetes mellitus. Cardiovasc Diabetol 2012; 11: 12.
33. Asahara S et al. Increased ribosomal biogenesis induces pancreatic beta cell failure in mice model of type 2 diabetes. Biochem Biophys Res Commun 2009; 381(3): 367-371.
34. Wang X et al. PAQR3 modulates insulin signaling by shunting phosphoinositide 3-kinase p110alpha to the Golgi apparatus. Diabetes 2013; 62(2): 444-456.
35. Matsuda T et al. Reduced insulin signaling and endoplasmic reticulum stress act synergistically to deteriorate pancreatic beta cell function. Kobe J Med Sci 2008; 54(2): E114-E121.
36. Mehta SH et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38(1): 50-56.
37. Lecube A et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29(5): 1096-1101.
38. Greca LF et al. Clinical features of patients with type 2 diabetes mellitus and hepatitis C infection. Braz J Med Biol Res 2011: 1-8.
39. Pyorala M et al. Hyperinsulinemia predicts coronary heart disease risk in healthy middleaged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98(5): 398-404.
40. Rewers M et al. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27(3): 781-787.
41. Folli F et al. Altered insulin receptor signalling and beta-cell cycle dynamics in type 2 diabetes mellitus. PLoS One 2011; 6(11): e28050.
42. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81(4A): 7B-12B.
43. Nordestgaard BG et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298(3): 299-308.
44. Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003; 5(Suppl 1): S19-S27.
45. Kawamoto R et al. Metabolic syndrome amplifies the LDL-cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44(12): 1232-1238.
46. Kathiresan S et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 2006; 113(1): 20-29.
47. Petersen KF et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007; 104(31): 12587-12594.
48. Nesto RW. LDL cholesterol lowering in type 2 diabetes: what is the optimum approach? Clin Diab 2008; 26: 8-13.
49. Matsuzawa Y et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24(1): 29-33.
50. Kumada M et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23(1): 85-89.
51. Tamang HK et al. Assessment of adiponectin level in obese and lean Nepalese population and its possible correlation with lipid profile: a cross-sectional study. Indian J Endocrinol Metab 2013; 17(Suppl 1): S349-S354.
52. Silha JV et al. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003; 149(4): 331-335.
53. Matsubara M, Maruoka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 2002; 147(2): 173-180.
54. Cohen SS et al. Serum adiponectin in relation to body mass index and other correlates in black and white women. Ann Epidemiol 2011; 21(2): 86-94.
55. Snehalatha C et al. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 2003; 26(12): 3226-3229.
56. Cruz M et al. Low adiponectin levels predict type 2 diabetes in Mexican children. Diabetes Care 2004; 27(6): 1451-1453.
57. Hung J et al. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond) 2008; 32(5): 772-779.
58. Wolfson N et al. Relation of adiponectin to glucose tolerance status, adiposity and cardiovascular risk factor load. Exp Diabetes Res 2012; 2012: 1-5.
59. Nagasawa H et al. High level of plasma adiponectin in acute stroke patients is associated with stroke mortality. J Neurol Sci 2011; 304(1-2): 102-106.
60. Ai M et al. Adiponectin: an independent risk factor for coronary heart disease in men in the Framingham offspring Study. Atherosclerosis 2011; 217(2): 543-548.
61. Wolf G, Ritz E. Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 2003; 14(5): 1396-1405.
62. Adler AI et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63(1): 225-232.
63. Triplitt CL. Understanding the kidneys' role in blood glucose regulation. Am J Manag Care 2012; 18(1 Suppl): S11-S16.
64. Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology 1982; 89(10): 1132-1145.
65. Kostev U et al. Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and UK. Prim Care Diabetes 2014.
66. Moser JT et al. The evaluation of peripheral neuropathy in youth with type 1 diabetes. Diabetes Res Clin Pract 2013; 100(1): e3-e6.
67. Tuomilehto J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England J Med 2001; 344(18): 1343-1350.
68. Yanai H et al. Dipeptidyl peptidase-4 inhibitor for steroid-induced diabetes. World J Diab 2010; 1(3): 99-100.
69. Baigent C et al. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366(9493): 1267-1278.
70. Muhlestein JB et al. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 2006; 48(2): 396-401.
71. Durrington PN et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85(5): 544-548.
72. Eldor R, Raz I. American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care 2009; 32(Suppl 2): S384-S391.
73. Bitzur R et al. Triglycerides and HDL cholesterol: stars or second leads in diabetes? Diabetes Care 2009; 32(Suppl 2): S373-S377.
74. Tabor HK, Risch NJ, Myers RM. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat Rev Genet 2002; 3(5): 391-397.
75. Kottgen A et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013; 45(2): 145-154.
76. Radha V, Mohan V. Genetic predisposition to type 2 diabetes among Asian Indians. Indian J Med Res 2007; 125(3): 259-274.
77. Menzaghi C et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002; 51(7): 2306-2312.
78. Wang H et al. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metabol 2002; 87(6): 2520-2524.
79. Shiota A et al. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc Diabetol 2012; 11: 139.
80. Silvestre MF et al. The AMPK-SIRT signaling network regulates glucose tolerance under calorie restriction conditions. Life Sci 2014; 100(1): 55-60.
81. Quarta C et al. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med 2011; 17(9): 518-526.
82. W-f SHAN et al. Effects of GLUT4 expression on insulin resistance in patients with advanced liver cirrhosis. J Zhejiang Univ-Sci B(Biomed& Biotechnol 2011; 12(8): 677-682.
83. Vasseur F et al. The genetics of adiponectin. Curr Diab Rep 2003; 3(2): 151-158.
84. Chiefari E et al. Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA 2011; 305(9): 903-912.
85. Wang H et al. Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes 2004; 53(8): 2132-2136.
86. Speakman JR. Thrifty genes for obesity and the metabolic syndrome-time to call off the search? Diab Vasc Dis Res 2006; 3(1): 7-11.
87. Mukherjee R et al. Novel peroxisome proliferator-activated receptor agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonists. J Pharmacol Exp Ther 2008; 327: 716-726.
88. Speakman JR. Thrifty genes for obesity, an attractive but flawed idea, and an alternative perspective: the 'drifty gene' hypothesis. Int J Obes (Lond) 2008; 32(11): 1611-1617.
89. Yamashita S et al. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta 2000; 1529(1-3): 257-275.
90. Hannuksela M et al. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res 1992; 33(5): 737-744.
91. Bernstein MS et al. No physical activity×CETP 1b.-629 interaction effects on lipid profile. Med Sci Sports Exerc 2003; 35(7): 1124-1129.
92. Ordovas JM et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000; 20(5): 1323-1329.
93. Hassanzadeh T et al. Taq1B polymorphism of cholesteryl ester transfer protein (CETP) gene in primary combined hyperlipidaemia. Indian J Med Res 2009; 129(3): 293-298.
94. Lopez-Rios L et al. Interaction between cholesteryl ester transfer protein and hepatic lipase encoding genes and the risk of type 2 diabetes: results from the Telde study. PLoS One 2011; 6(11): e27208.
95. Wang J et al. CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population. Lipids Health Dis 2013; 12: 176.
96. Wang Q et al. Seven functional polymorphisms in the CETP gene and myocardial infarction risk: a meta-analysis and meta-regression. PLoS One 2014; 9(2): e88118.
97. Ridker PM et al. Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet 2009; 2(1): 26-33.
98. Ilhan N et al. Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct 2007; 25(5): 527-532.
99. Eto M et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis 2002; 40(2): 243-251.
100. Satirapoj B et al. Apolipoprotein E genetic polymorphisms and the development of nephropathy in type 2 diabetes. J Med Assoc Thai 2013; 96(9): 1119-1126.
101. Chaudhary R et al. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol 2012; 11: 36.
102. Pennacchio LA et al. Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet 2002; 11(24): 3031-3038.
103. Talmud PJ et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet 2002; 11(24): 3039-3046.
104. Lamia R et al. Association of four apolipoprotein B polymorphisms with lipid profile and stenosis in Tunisian coronary patients. J Genet 2012; 91(1): 75-79.
105. Gallegos-Arreola MP et al. Association between the Xba I polymorphism of APOB gene and plasma lipid level in Mexican patients with coronary artery disease. Asia Pac J Clin Nutr 2012; 21(2): 312-318.
106. Masson LF, McNeill G, Avenell A. Genetic variation and the lipid response to dietary intervention: a systematic review. Am J Clin Nut 2003; 77(5): 1098-1111.
107. Frikke-Schmidt R et al. Single nucleotide polymorphism in the low-density lipoprotein receptor is associated with a threefold risk of stroke. A case control and prospective study. Eur Heart J 2004; 25(11): 943-951.
108. Ye H et al. Meta-analysis of low density lipoprotein receptor (LDLR) rs2228671 polymorphism and coronary heart disease. BioMed Res Int 2014; 2014: 1-6.
109. Martinelli N et al. Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile. Blood 2010; 116(25): 5688-5697.
110. Lye SH et al Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia. PLoS One 2013; 8(4): e60729.
111. Khoshi A et al. Relationship between PON1L55M and Q192R gene polymorphisms and high APO B/APO A-I ratios. Indian J Clin Biochem 2009; 24(4): 381-387.
112. Ho KT et al. Association of interleukin-4 promoter polymorphisms in Taiwanese patients with type 2 diabetes mellitus. Metabolism 2010; 59(12): 1717-1722.
113. Chang YH, Huang CN, Shiau MY. Association of IL-4 receptor gene polymorphisms with high density lipoprotein cholesterol. Cytokine 2012; 59(2): 309-312.
114. Clee SM et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001; 103(9): 1198-1205.
115. Solini A et al. Lipoprotein lipase gene variants and progression of nephropathy in hypercholesterolaemic patients with type 2 diabetes. J Intern Med 2004; 256(1): 30-6.
116. Mingrone G et al. Effects of insulin on hepatic lipid synthesis in alloxan diabetic rats. Exp Pathol (Jena) 1979; 17(9): 533-538.
117. Fowden AL. The role of insulin in fetal growth. Early Hum Dev 1992; 29(1-3): 177-181.
118. He L et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137(4): 635-646.
119. Jenkins NT et al. Differential vasomotor effects of insulin on gastrocnemius and soleus feed arteries in the OLETF rat model: role of endothelin-1. Exp Physiol 2014; 99(1): 262-271.
120. Zhao K et al. Insulin stimulates glucose uptake via a phosphatidylinositide 3-kinase-linked signaling pathway in bovine mammary epithelial cells. J Dairy Sci 2014; 97(6): 3660-3665.
121. Boucher BJ et al. Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in east London Asians. Diabetologia 1995; 38(10): 1239-1245.
122. Fernandez-Figares I et al. The role of insulin, glucagon, dexamethasone, and leptin in the regulation of ketogenesis and glycogen storage in primary cultures of porcine hepatocytes prepared from 60 kg pigs. Domest Anim Endocrinol 2004; 27(2): 125-140.
123. Li XY et al. Mechanisms of hepatocyte growth factor-mediated signaling in differentiation of pancreatic ductal epithelial cells into insulin-producing cells. Biochem Biophys Res Commun 2010; 398(3): 389-394.
124. Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379-388.
125. Brown JE, Dunmore SJ. Leptin decreases apoptosis and alters BCL-2: Bax ratio in clonal rodent pancreatic beta-cells. Diabetes Metab Res Rev 2007; 23(6): 497-502.
126. Pallett AL et al. Leptin inhibits insulin secretion and reduces insulin mRNA levels in rat isolated pancreatic islets. Biochem Biophys Res Commun 1997; 238(1): 267-270.
127. Reaux A et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001; 77(4): 1085-1096.
128. Guo L et al. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3- kinase-phosphodiesterase 3B. Endocr Res 2009; 34(4): 142-154.
129. Chen MM et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003; 108(12): 1432-1439.
130. Gu W et al. Globular adiponectin augments insulin secretion from pancreatic islet beta cells at high glucose concentrations. Endocrine 2006; 30(2): 217-221.
131. Zhang M et al. Abnormal adipokines associated with various types of obesity in Chinese children and adolescents. Biomed Environ Sci 2011; 24(1): 12-21.
132. Brown JE et al. Regulation of beta-cell viability and gene expression by distinct agonist fragments of adiponectin. Peptides 2010; 31(5): 944-949.
133. Brown JE, Onyango DJ, Dunmore SJ. Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett 2007; 581(17): 3273-3276.
134. Hivert MF et al. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metabol 2008; 93(8): 3165-3172.
135. Qi Q et al. Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur J Endocrinol 2008; 159(5): 585-593.
136. Takebayashi K et al. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007; 56(4): 451-458.
137. Otani K et al. Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in betaIRKO mice. Am J Physiol Endocrinol Metab 2004; 286(1): E41-E49.
138. Brown JE et al. Visfatin regulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells. J Mol Endocrinol 2010; 44(3): 171-178.
139. Revollo JR et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6(5): 363-375.